Services
Medicinal Chemistry
Primary screening studies initially generate a list of compounds with the required biological activities (‘Hits’). These Hits rarely fulfil all the criteria for a quality 'tool' compound as they typically show only a moderate affinity for the target and restricted selectivity.
To become a useful tool compound, the chemical properties of the initial Hits must therefore be iteratively improved by suitable structural modification. The post-screening Hit-to-tool optimisation process is carried out by accredited chemistry partner sites in EU-OPENSCREEN ERIC Member countries and is organised as a research collaboration between the assay provider and the respective chemistry site.
Apply for funding
Currently, the European Commission offers project funding for medicinal chemistry support in our EU-OPENSCREEN ERIC partner sites through the ISIDORe project. Read more here.
Medicinal chemistry partner sites
CZECH REPUBLIC
Masaryk University (MU) – Laboratory of Organic Synthesis and Medicinal Chemistry
Dr. Kamil Paruch
Germany
Helmholtz-Centre for Infection Research – Braunschweig
Department of Chemical Biology (CBIO)
Prof. Mark Brönstrup
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) – Medicinal Chemistry
Dr. Marc Nazaré
SPAIN
Consejo Superior de Investigaciones Científicas – Madrid (CIB-CSIC)
Translational Medicinal and Biological Chemistry Laboratory
Prof. Dr. Ana Martínez
Dr. Carmen Gil
Institute of Biomedicine of the University of Barcelona (IBUB-UB)
Laboratory of Medicinal Chemistry
Prof. Rodolfo Lavilla
POLAND
Institute of Biochemistry and Biophysics (IBB PAS)
Prof. Dr. Piotr Zielenkiewicz
PORTUGAL
University of Lisbon - Research Institute for Medicines (iMed.ULisboa)
Rui Moreira
University of Porto - Chemistry Research Centre (FCUP)
Fernanda Borges
SWEDEN
Karolinska Institutet - Department Medical Biochemistry and Biophysics (CBCS-KI)
Anna-Lena Gustavsson
Umeå University - Chemical Biology Centre (CBCS-UmU)
Erik Chorell